Richard P. Slaughter Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Richard P. Slaughter Associates’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,036	Closed	-$491K	–	103
2025 Q4	$491K	Hold	21,036	–	–	0.1%	70
2025 Q3	$414K	Sell	21,036 -35,844	-63%	-$737K	0.09%	82
2025 Q2	$1.23M	Sell	56,880 -54,614	-49%	-$1.29M	0.25%	52
2025 Q1	$2.7M	Sell	111,494 -37,912	-25%	-$854K	0.63%	30
2024 Q4	$3.12M	Buy	149,406 +2,770	+2%	+$59.5K	0.7%	33
2024 Q3	$2.92M	Sell	146,636 -15,567	-10%	-$289K	0.68%	36
2024 Q2	$2.51M	Buy	+162,203	New	+$2.53M	0.59%	41

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Richard P. Slaughter Associates's CPRX Position: Q1 2026 in Review

Richard P. Slaughter Associates sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 21,036 shares — an estimated $491K sold.

Richard P. Slaughter Associates first reported a position in CPRX in Q2 2024 and held it in 7 quarters. The position peaked at $3.12M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Richard P. Slaughter Associates reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Richard P. Slaughter Associates sold 21,036 Catalyst Pharmaceutical shares in Q1 2026, an estimated $491K.
Richard P. Slaughter Associates first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 7 quarters.
Richard P. Slaughter Associates's Catalyst Pharmaceutical position peaked at $3.12M in Q4 2024.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Richard P. Slaughter Associates's 13F filing for Q1 2026, filed 13 Apr 2026.